To provide a comprehensive review to determine whether there is a class effect among angiotensin receptor blockers (ARBs) in relation to serum uric acid.
Summary:
A literature search was conducted and 8 articles were identified for inclusion in this review. In the studies reviewed, candesartan and valsartan were shown to have either a neutral or negative effect on serum uric acid. Azilsartan was shown to have a negative impact on serum uric acid while eprosartan appeared to have no impact on serum uric acid levels. Irbesartan demonstrated either a neutral or positive effect on serum uric acid while losartan exhibited a positive effect.
Conclusion:
The available data indicate that the reduction of serum uric acid is not a class effect of ARBs. Of the available agents, only losartan has clear evidence of its ability to lower serum uric acid. For patients with high blood pressure and elevated serum uric acid, losartan should be considered as a first-line agent with irbesartan as an alternative when appropriate.
BenjaminEJBlahaMJChiuveSE, et al.Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–e603.
2.
WheltonPKCareyRMAronowWS, et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a REPORT of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2017;71(6):1269–1324.
American Diabetes A. Microvascular complications and foot care. Diabetes Care. 2015;38(suppl):S58–66.
12.
AmsterdamEAWengerNKBrindisRG, et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart association task force on practice guidelines. Circulation. 2014;130(25):2354–2394.
13.
O’GaraPTKushnerFGAscheimDD, et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart association task force on practice guidelines. J Am Coll Cardiol. 2013;61(4):485–510.
14.
YancyCWJessupMBozkurtB, et al.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–e161.
15.
KhannaDFitzgeraldJDKhannaPP, et al.2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–1446.
16.
QaseemAHarrisRPForcieaMA. Management of acute and recurrent gout: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2017;166(1):58–68.
17.
ZhuYPandyaBJChoiHK. Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–3141.
18.
DoehnerWSchoeneNRauchhausM, et al.Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105(22):2619–2624.
19.
IwanagaTSatoMMaedaT, et al.Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007;320(1):211–217.
20.
HarrisRPMcLeanRMQaseemA. Management of acute and recurrent gout. Ann Intern Med. 2017;166(10):760.
21.
BurnierMRutschmannBNussbergerJ, et al.Salt-dependent renal effects of and angiotensin II antagonist in healthy subjects. Hypertension. 1993;22(3):339–347.
22.
HamadaTHisatomeIKinugasaY, et al.Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med. 2002;41(10):793–797.
23.
ChoiHKSorianoLCZhangY, et al.Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190.
24.
HamadaTIchidaKHosoyamadaM, et al.Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertension. 2008;21(10):1157–1162.
25.
NakamuraMSasaiNHisatomeI, et al.Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol. 2014;6:79–86.
26.
WolffMLCruzJLVandermanAJ, et al.The effect of angiotensin II receptor blockers on hyperuricemia. Ther Adv Chronic Dis. 2015;6(6):339–346.
27.
RaynerBTrinderYBainesD, et al.Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens. 2006;19:208–213.
28.
WürznerGGersterJChioleroA, et al.Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001;19:1855–1860.
29.
KhanMMashoriGMemonK. Safety of losartan in hypertensive patients with thiazide induced hyperuricemia. J Liaquat Univ Med Health Sci. 2008;7:163–167.
30.
KhanMKhanRIslamF, et al.To study the efficacy of losartan on urinary uric acid excretion in thiazide induced hyperuricemic and hypertensive patients. Pak J Pharm Sci. 2011;24:583–587.
31.
DangAZhangYLiuG, et al.Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens. 2006;20:45–50.
32.
ElisafMTsimichodimosVBairaktariE, et al.Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol. 1999;34:60–63.
33.
ShahinfarSSimpsonRCaridesA, et al.Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. 1999;56:1879–1885.
34.
TakahasiSMoriwakiYYamamotoT, et al.Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62:572–575.
35.
ChidaRHisauchiIToyodaS, et al.Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients. Hypertens Res. 2015;38(11):765–769.
36.
ElliottWJCalhounDADeLuccaPT, et al.Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther. 2001;23(8):1166–1179.
37.
MonterrosoVHRodriguez ChavezVCarbajalET, et al.Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan trial investigators. Adv Ther.2000;17(2):117–131.
38.
PuigJGMateosFBunoA, et al.Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens. 1999;17(7):1033–1039.
39.
ShigaYMiuraSIMotozatoK, et al.Comparison of efficacy and safety of azilsartan and olmesartan in patients with essential hypertension. Int Heart J. 2017;58(3):416–421.
40.
MorgansenUMKoberLJhundPS, et al.Sacubitril/valsartan reduces serum uric acid concentrations, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail. 2018;20(3):514–522.
41.
HamadaTMizutaEKondoT, et al.Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients. Arzneimittelforschung. 2010;60(2):71–75.
